Nucleome Therapeutics
Generated by Meeveem AI
"Decoding the regulatory genome to discover precision medicines for inflammatory diseases"
About Nucleome Therapeutics
Nucleome Therapeutics is an Oxford biotechnology company using 3D genomics to discover precision medicines for inflammatory diseases. It links disease-associated genetic variants in the regulatory genome to the genes they affect, identifying potential drug targets in human immune cells. Its work addresses conditions including rheumatoid arthritis, lupus and inflammatory bowel disease.
The company combines laboratory research with machine learning to map how variants alter gene expression. Its atlas covers hundreds of dysregulated genes across four major inflammatory diseases. Founded as an Oxford University spin-out in 2019, Nucleome is developing antibody medicines, including the preclinical programme NTP464, alongside targets for internal development and pharmaceutical partnerships.
Research teams
Nucleome brings together scientists with expertise in genetics, antibodies, CRISPR and laboratory methods. Its careers material describes work spanning computational biology and drug discovery, with machine learning and experimental research contributing to the same development effort.
44
Team Members
2019
Founded
Biotechnology
Sector
Hybrid
Work Environment